204 related articles for article (PubMed ID: 28797967)
1. Multipurpose tenofovir disoproxil fumarate electrospun fibers for the prevention of HIV-1 and HSV-2 infections in vitro.
Tyo KM; Vuong HR; Malik DA; Sims LB; Alatassi H; Duan J; Watson WH; Steinbach-Rankins JM
Int J Pharm; 2017 Oct; 531(1):118-133. PubMed ID: 28797967
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of poly(lactic-co-glycolic acid) and poly(dl-lactide-co-ε-caprolactone) electrospun fibers for the treatment of HSV-2 infection.
Aniagyei SE; Sims LB; Malik DA; Tyo KM; Curry KC; Kim W; Hodge DA; Duan J; Steinbach-Rankins JM
Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():238-251. PubMed ID: 28024582
[TBL] [Abstract][Full Text] [Related]
3. Computational Modeling of Antiviral Drug Diffusion from Poly(lactic- co-glycolic-acid) Fibers and Multicompartment Pharmacokinetics for Application to the Female Reproductive Tract.
Halwes ME; Tyo KM; Steinbach-Rankins JM; Frieboes HB
Mol Pharm; 2018 Apr; 15(4):1534-1547. PubMed ID: 29481088
[TBL] [Abstract][Full Text] [Related]
4. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
[TBL] [Abstract][Full Text] [Related]
5. Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV Infection.
Grooms TN; Vuong HR; Tyo KM; Malik DA; Sims LB; Whittington CP; Palmer KE; Matoba N; Steinbach-Rankins JM
Antimicrob Agents Chemother; 2016 Nov; 60(11):6518-6531. PubMed ID: 27550363
[TBL] [Abstract][Full Text] [Related]
6. pH-responsive delivery of Griffithsin from electrospun fibers.
Tyo KM; Duan J; Kollipara P; Dela Cerna MVC; Lee D; Palmer KE; Steinbach-Rankins JM
Eur J Pharm Biopharm; 2019 May; 138():64-74. PubMed ID: 29698714
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
Callebaut C; Stepan G; Tian Y; Miller MD
Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
[TBL] [Abstract][Full Text] [Related]
8. Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.
Destache CJ; Mandal S; Yuan Z; Kang G; Date AA; Lu W; Shibata A; Pham R; Bruck P; Rezich M; Zhou Y; Vivekanandan R; Fletcher CV; Li Q
Antimicrob Agents Chemother; 2016 Jun; 60(6):3633-9. PubMed ID: 27044548
[TBL] [Abstract][Full Text] [Related]
9. Tunable Release of Multiclass Anti-HIV Drugs that are Water-Soluble and Loaded at High Drug Content in Polyester Blended Electrospun Fibers.
Carson D; Jiang Y; Woodrow KA
Pharm Res; 2016 Jan; 33(1):125-36. PubMed ID: 26286184
[TBL] [Abstract][Full Text] [Related]
10. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission.
Zhang T; Sturgis TF; Youan BB
Eur J Pharm Biopharm; 2011 Nov; 79(3):526-36. PubMed ID: 21736940
[TBL] [Abstract][Full Text] [Related]
11. The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.
Seay K; Khajoueinejad N; Zheng JH; Kiser P; Ochsenbauer C; Kappes JC; Herold B; Goldstein H
J Virol; 2015 Sep; 89(18):9559-70. PubMed ID: 26157126
[TBL] [Abstract][Full Text] [Related]
12. Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system.
Machado A; Cunha-Reis C; Araújo F; Nunes R; Seabra V; Ferreira D; das Neves J; Sarmento B
Acta Biomater; 2016 Oct; 44():332-40. PubMed ID: 27544812
[TBL] [Abstract][Full Text] [Related]
13. Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety.
Nixon B; Jandl T; Teller RS; Taneva E; Wang Y; Nagaraja U; Kiser PF; Herold BC
Antimicrob Agents Chemother; 2014; 58(2):1153-60. PubMed ID: 24323471
[TBL] [Abstract][Full Text] [Related]
14. Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study.
Celum C; Hong T; Cent A; Donnell D; Morrow R; Baeten JM; Firnhaber C; Grinsztejn B; Hosseinipour MC; Lalloo U; Nyirenda M; Riviere C; Sanchez J; Santos B; Supparatpinyo K; Hakim J; Kumarasamy N; Campbell TB;
J Infect Dis; 2017 Mar; 215(6):907-910. PubMed ID: 28453835
[TBL] [Abstract][Full Text] [Related]
15. Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.
Chaowanachan T; Krogstad E; Ball C; Woodrow KA
PLoS One; 2013; 8(4):e61416. PubMed ID: 23630586
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
Moss JA; Malone AM; Smith TJ; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Vincent KL; Motamedi M; Friend DR; Clark MR; Baum MM
Antimicrob Agents Chemother; 2012 Feb; 56(2):875-82. PubMed ID: 22123689
[TBL] [Abstract][Full Text] [Related]
17. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
Margot NA; Liu Y; Miller MD; Callebaut C
Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
[TBL] [Abstract][Full Text] [Related]
18. Herpes simplex virus type-2 stimulates HIV-1 replication in cervical tissues: implications for HIV-1 transmission and efficacy of anti-HIV-1 microbicides.
Rollenhagen C; Lathrop MJ; Macura SL; Doncel GF; Asin SN
Mucosal Immunol; 2014 Sep; 7(5):1165-74. PubMed ID: 24496317
[TBL] [Abstract][Full Text] [Related]
19. Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission.
Friend DR
Expert Opin Drug Deliv; 2012 Apr; 9(4):417-27. PubMed ID: 22385316
[TBL] [Abstract][Full Text] [Related]
20. Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections.
Tyo KM; Lasnik AB; Zhang L; Mahmoud M; Jenson AB; Fuqua JL; Palmer KE; Steinbach-Rankins JM
J Control Release; 2020 May; 321():84-99. PubMed ID: 32035194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]